CG
CGTX.US Cognition Therapeutics Inc
- Market cap
- USD 64.6M
- P/E
- -
- P/B
- 2.20x
- ROE
- -57.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CGTX.US undervalued?
Graham numberThe Graham number of Cognition Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cognition Therapeutics Inc fundamental analysis
No fundamental analysis for Cognition Therapeutics Inc yet.
Cognition Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzhe…
Full company profileCognition Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cognition Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -81.0K | -98.0K | -93.0K | -235K | -252K | -266K | -228K | - |
| Operating Income | -17.8M | -17.4M | -28.6M | -43.6M | -50.7M | -54.0M | -47.8M | -31.9M |
| EBITDA | -3.74M | -5.99M | -10.7M | -21.1M | -25.5M | -33.7M | -23.2M | -16.6M |
| Net Income | -6.95M | -10.1M | -11.7M | 757K | -25.8M | -34.0M | -23.5M | -16.9M |
| EPS | -0.32 | -0.46 | -0.53 | 0.03 | -0.86 | -0.86 | -0.32 | -0.18 |
| Balance Sheet | ||||||||
| Total Assets | 7.46M | 7.12M | 59.1M | 50.4M | 35.2M | 30.2M | 48.4M | 34.8M |
| Total Liabilities | 65.9M | 75.3M | 7.86M | 10.2M | 10.7M | 11.5M | 14.1M | 5.53M |
| Shareholders' Equity | -58.4M | -68.2M | 51.3M | 40.2M | 24.5M | 18.8M | 34.3M | 29.3M |
| Cash & Short-term Investments | 2.89M | 5.19M | 54.7M | 41.6M | 29.9M | 25.0M | 36.8M | 30.8M |
| Total Debt | 6.90M | 12.9M | - | 1.48M | 1.24M | 814K | 638K | 489K |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.10M | -3.43M | -3.63M | -18.5M | -16.0M | -28.5M | -24.6M | -15.8M |
| Capital Expenditure | 144K | 10.0K | 27.0K | 171K | 147K | 4.00K | 0.00 | 53.3K |
| Free Cash Flow | -3.24M | -3.44M | -3.66M | -18.7M | -16.2M | -28.5M | -24.6M | -15.8M |
| Ratios | ||||||||
| ROE | - | - | -22.9% | 1.9% | -105.4% | -181.2% | -68.5% | -57.6% |
| ROA | -93.2% | -141.5% | -19.8% | 1.5% | -73.3% | -112.4% | -48.5% | -48.5% |
| Debt to Equity | - | - | - | 0.04x | 0.05x | 0.04x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cognition Therapeutics Inc dividends
Cognition Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Cognition Therapeutics Inc
- Insiders 1.30%
- Institutions 23.50%
- Public & others 75.20%
- Shares outstanding 95.1M
- Free float 87.5M
Top funds holding CGTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.44M | 2.57% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 430K | 0.45% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 250K | 0.26% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 144K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 119K | 0.12% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 84.9K | 0.09% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 38.8K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 31.8K | 0.03% | 0.00% | Sep 2026 |
| Gabelli Global Mini Mites I | 30.0K | 0.03% | 0.00% | Jun 2026 |
| Vanguard U.S. Eq Idx £ Acc | 23.6K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 18.4K | 0.02% | 0.00% | Sep 2026 |
| iShares Neuroscience and Healthcare ETF | 10.7K | 0.01% | +25.29% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 5.76K | 0.01% | -88.72% | Aug 2026 |
Top institutions holding CGTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BIOS CAPITAL MANAGEMENT, LP | 6.00M | 6.31% | 0.00% | Jun 2026 |
| Davenport & Company LLC | 4.26M | 4.48% | +47.24% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.44M | 3.62% | +14.56% | Jun 2026 |
| BlackRock Inc | 1.26M | 1.33% | +30.32% | Jun 2026 |
| Chescapmanager LLC | 997K | 1.05% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 910K | 0.96% | -1.11% | Jun 2026 |
| Renaissance Technologies Corp | 693K | 0.73% | -37.94% | Jun 2026 |
| Hilton Capital Management, LLC | 549K | 0.58% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 508K | 0.53% | +9.60% | Jun 2026 |
| CM Management, LLC | 450K | 0.47% | +12.50% | Jun 2026 |
| Dauntless Investment Group, LLC | 372K | 0.39% | -13.76% | Jun 2026 |
| Sigma Planning Corp | 362K | 0.38% | +7.25% | Jun 2026 |
| State Street Corp | 349K | 0.37% | +10.97% | Jun 2026 |
| Tocqueville Asset Management L.P. | 321K | 0.34% | +64.36% | Jun 2026 |
| UBS Group AG | 219K | 0.23% | +184.28% | Jun 2026 |
| American Financial Group Inc | 205K | 0.22% | 0.00% | Jun 2026 |
| Northern Trust Corp | 178K | 0.19% | +5.64% | Jun 2026 |
| Voss Capital LLC | 175K | 0.18% | -12.50% | Jun 2026 |
| Texas Capital Bank Wealth Management Services Inc | 143K | 0.15% | +16.22% | Jun 2026 |
| Charles Schwab Investment Management Inc | 84.9K | 0.09% | 0.00% | Jun 2026 |
Cognition Therapeutics Inc company profile
- Company name
- Cognition Therapeutics Inc
- Ticker
- CGTX.US
- Exchange
- USA Stocks
- Listed since
- Oct 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 2500 Westchester Ave., Purchase, NY, United States, 10577
- Phone
- 412 481 2210
- Website
- cogrx.com
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Cognition Therapeutics Inc management
6- Ms. Lisa RicciardiCEO, President & Director · born 1960
- Mr. John Brendan DoyleChief Financial Officer · born 1977
- Dr. Anthony O. Caggiano M.D., Ph.D.Chief Medical Officer · born 1970
- Dr. Steven A. Weissman Ph.D.VP & Head of CMC
- Ms. Anita CornetHead of Quality
- Mr. Bobby HornCorporate Controller